BIOTRONIK's 360o CRT technologies are designed to better equip physicians to meet the therapy needs of heart failure patients. These technologies include:

MultiPole Pacing – enables left ventricle to be paced sequentially or simultaneously
MRI AutoDetect – shortens window of reduced therapy and eliminates the need for post-MRI reprogramming

Closed Loop Stimulation – equips the device to respond appropriately to physiologic demands and acute mental stress
Ultra-High Energy CRT defibrillator – provides up to 42J of energy to meet patient needs on first and every shock
CRT-DX system – allows full CRT-D therapy with only two leads
The thinnest leads approved for use in MR conditional CRT systems, including Sentus ProMRI QP, also launched today.

BIOTRONIK Home Monitoring® – automatically transmits device data daily; proven to reduce mortality in patients with heart failure by 50%3
Heart Rhythm attendees are encouraged to visit BIOTRONIK's booth (#820) to learn more about MPP and other 360o CRT solutions.


About BIOTRONIK
A global leader in cardio- and endovascular medical technology, BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries. Several million patients have received BIOTRONIK implants designed to save and improve the quality of their lives, or have been treated with BIOTRONIK coronary and peripheral vascular intervention products. Since its development of the first German pacemaker in 1963, BIOTRONIK has engineered many innovations, including Magmaris*, the first clinically-proven resorbable magnesium scaffold; BIOTRONIK Home Monitoring®; Pulsar-18, the world's first 4 F compatible stent for treating long lesions; Orsiro**, the industry's first hybrid drug-eluting stent; and the world's first implantable cardioverter defibrillators and heart failure therapy devices with ProMRI® technology.

Back to HCB News

Cardiology Homepage